share_log

This CVS Health Insider Reduced Their Stake By 40%

This CVS Health Insider Reduced Their Stake By 40%

這位西維斯健康內部人士減持了40%的股份
Simply Wall St ·  10/02 22:39

Insiders were net sellers of CVS Health Corporation's (NYSE:CVS ) stock during the past year. That is, insiders sold more stock than they bought.

過去一年中,內部股東是西維斯健康股份公司(紐交所: CVS)股票的淨賣出者。 也就是說,內部股東賣出的股票比他們買入的要多。

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

雖然我們絕不會建議投資者僅僅基於公司董事們的行動來做決定,但我們認爲跟蹤內部人士的行動是非常合理的。

CVS Health Insider Transactions Over The Last Year

上個財年西維斯健康內部交易情況

Over the last year, we can see that the biggest insider sale was by the Executive VP, Prem Shah, for US$2.3m worth of shares, at about US$76.95 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$61.54). So it may not shed much light on insider confidence at current levels. The only individual insider seller over the last year was Prem Shah.

在過去的一年裏,我們可以看到,執行副總裁Shah貝姆以每股約76.95美元的價格出售了價值230萬美元的股票,這是最大規模的內部賣出。雖然內部賣出是不利的,但對我們來說,如果股票的售價較低,則情況更爲糟糕。值得一提的是,這次減持是在最新股價(61.54美元)之上發生的。因此,在當前水平上,這可能並未太多地反映內部人士的信心。過去一年中唯一一位內部個人賣家是Prem Shah。

In the last twelve months insiders purchased 12.18k shares for US$695k. But they sold 29.47k shares for US$2.3m. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

在過去的十二個月中,內部人士購買了12,180股,總價69.5萬美元。但他們賣出了29,470股,總價230萬美元。您可以在下面的圖表中看到過去一年內部人員(公司和個人)的交易情況。點擊下方的圖表,您可以查看每筆內部交易的詳細信息!

big
NYSE:CVS Insider Trading Volume October 2nd 2024
紐交所:西維斯健康內部交易量2024年10月2日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

如果你喜歡購買內部人員正在購買而不是銷售的股票,那麼你可能會喜歡這份免費的公司列表。(提示:它們中的大部分都被忽視了。)

Insider Ownership

內部人員持股情況

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. CVS Health insiders own about US$120m worth of shares (which is 0.2% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

許多投資者喜歡查看公司內部持股情況。高比例的內部持股通常會使公司管理層更加關注股東利益。西維斯健康內部持有價值約1.2億美元的股份(佔公司總股本的0.2%)。內部人士擁有如此大比例的股份通常會增加公司以所有股東利益爲導向的可能性。

What Might The Insider Transactions At CVS Health Tell Us?

西維斯健康內部交易可能會告訴我們什麼?

It doesn't really mean much that no insider has traded CVS Health shares in the last quarter. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of CVS Health insider transactions don't fill us with confidence. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing CVS Health. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of CVS Health.

過去一個季度內沒有內部人士交易西維斯健康股份並不意味着什麼。對內部人士擁有大量股份感到欣慰,但我們希望看到更多內部買入交易,因爲西維斯健康過去一年的內部交易並沒有給我們帶來信心。除了了解正在發生的內部交易,了解西維斯健康面臨的風險也是有益的。爲了幫助您,我們發現了1個警示信號,您應該仔細審查以更全面地了解西維斯健康。

But note: CVS Health may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意:西維斯健康可能不是買入的最佳股票。所以看看這份免費的有趣公司名單,其中roe高且債務低。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論